Wehland J, Willingham M C, Sandoval I V
J Cell Biol. 1983 Nov;97(5 Pt 1):1467-75. doi: 10.1083/jcb.97.5.1467.
The antigenic site recognized by a rat monoclonal antibody (clone YL 1/2) reacting with alpha-tubulin (Kilmartin, J.V., B. Wright, and C. Milstein, 1982, J. Cell Biol., 93:576-582) has been determined and partially characterized. YL 1/2 reacts specifically with the tyrosylated form of brain alpha-tubulin from different mammalian species. YL 1/2 reacts with the synthetic peptide Gly-(Glu)3-Gly-(Glu)2-Tyr, corresponding to the carboxyterminal amino acid sequence of tyrosylated alpha-tubulin, but does not react with Gly-(Glu)3-Gly-(Glu)2, the constituent peptide of detyrosylated alpha-tubulin. Electron microscopy as well as direct and indirect immunofluorescence microscopy shows that YL 1/2 binds to the surface of microtubules polymerized in vitro and in vivo. Further in vitro studies show that the antibody has no effect on the rate and extent of microtubule polymerization, the stability of microtubules, and the incorporation of the microtubule-associated proteins (MAP2) and tau into microtubules. In vivo studies using Swiss 3T3 fibroblasts injected with YL 1/2 show that; when injected at low concentration (2 mg IgG/ml in the injection solution), the antibody binds to microtubules without changing their distribution in the cytoplasm. Injection of larger concentration of YL 1/2 (6 mg IgG/ml) induces the formation of microtubule bundles, and still higher concentrations cause the aggregation of microtubule bundles around the nucleus (greater than 12 mg IgG/ml).
一种与α-微管蛋白反应的大鼠单克隆抗体(克隆YL 1/2)所识别的抗原位点已被确定并进行了部分特性描述(Kilmartin, J.V., B. Wright, and C. Milstein, 1982, J. Cell Biol., 93:576 - 582)。YL 1/2与来自不同哺乳动物物种的脑α-微管蛋白的酪氨酰化形式特异性反应。YL 1/2与合成肽Gly-(Glu)3-Gly-(Glu)2-Tyr反应,该肽对应于酪氨酰化α-微管蛋白的羧基末端氨基酸序列,但不与去酪氨酰化α-微管蛋白的组成肽Gly-(Glu)3-Gly-(Glu)2反应。电子显微镜以及直接和间接免疫荧光显微镜显示,YL 1/2结合到体外和体内聚合的微管表面。进一步的体外研究表明,该抗体对微管聚合的速率和程度、微管的稳定性以及微管相关蛋白(MAP2)和tau掺入微管均无影响。使用注射了YL 1/2的瑞士3T3成纤维细胞进行的体内研究表明,当以低浓度(注射溶液中2 mg IgG/ml)注射时,该抗体结合到微管上而不改变其在细胞质中的分布。注射更高浓度的YL 1/2(6 mg IgG/ml)会诱导微管束的形成,更高的浓度(大于12 mg IgG/ml)会导致微管束在细胞核周围聚集。